Stocks and Investing
Stocks and Investing
Thu, March 23, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (CDTX) at Strong Buy with Decreased Target to $120 on, Mar 23rd, 2023
Ed Arce of HC Wainwright & Co., Maintained "Cidara Therapeutics, Inc." (CDTX) at Strong Buy with Decreased Target from $130 to $120 on, Mar 23rd, 2023.
Ed has made no other calls on CDTX in the last 4 months.
There is 1 other peer that has a rating on CDTX. Out of the 1 peers that are also analyzing CDTX, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $100 on, Wednesday, March 8th, 2023
Contributing Sources